top of page
Search

EVI at ASTMH 2025: Advancing maternal health through placental malaria vaccine research

  • Writer: EVI
    EVI
  • 4 days ago
  • 2 min read

Updated: 24 minutes ago

The European Vaccine Initiative (EVI) was proud to participate in the American Society of Tropical Medicine and Hygiene (ASTMH) 2025 Annual Meeting, one of the world’s leading gatherings of experts dedicated to tropical and global health.

November 2025


Dr Nicola Viebig, EVI’s Director of Research at ASTMH 2025 in Toronto, Canada.
Dr Nicola Viebig, EVI’s Director of Research at ASTMH 2025 in Toronto, Canada.

Dr Nicola Viebig, Director of Research at EVI, attended the meeting to engage with global health experts and share EVI’s work on vaccine research and development.

This year, EVI’s dedication to improving maternal and neonatal health was highlighted, with a focus on the development of a placental malaria vaccine, a vital innovation for protecting mothers and babies in malaria-endemic regions.


As part of the ADVANCE-VAC4PM and VAC4PM projects, several collaborators presented new findings that advance understanding of placental malaria and vaccine-induced immune responses:


  • Eizo Takashima (Ehime University) presented a poster on “Cross-reactivity of PRIMVAC- and PAMVAC-induced antibodies to VAR2CSA antigens from representative field isolates”, providing valuable insights into how vaccine-induced antibodies recognise diverse malaria parasite strains. (VAC4PM)


  • Issa Nébié (GRAS) delivered an oral presentation on “Persistence of IgG antibody responses in women immunised with the PRIMVAC placental malaria vaccine candidate in Burkina Faso, five to six years post-vaccination”, highlighting the durability of PRIMVAC-induced immune responses years after vaccination. (VAC4PM)


Dr Issa Nébié shared recent data on the durability of the PRIMVAC-induced immune response.
Dr Issa Nébié shared recent data on the durability of the PRIMVAC-induced immune response.

  • David Dosoo (Kintampo Health Research Centre) presented a poster on “Evaluation of a mobile application for tracking pregnancy outcomes”, showcasing innovative digital approaches to support maternal health research. (ADVANCE_VAC4PM)


EVI’s participation at ASTMH 2025 underscores its long-standing commitment to advancing vaccine research for vulnerable populations and fostering collaboration through international partnerships. By supporting the development of a safe and effective placental malaria vaccine, EVI and its partners continue to work towards a future where pregnancy is safer for women living in malaria-endemic regions.


Left to right: Dr David Dosoo, from KHRC, presenting his poster on digital tools for pregnancy monitoring; Dr Eizo Takashima, Ehime University, presented a poster on vaccine-induced antibodies recognising diverse malaria parasite strains.


ree

ADVANCE-VAC4PM is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.



ree

VAC4PM has received funding from Global Health Innovative Technology Fund (GHIT).

 
 
bottom of page